Clinical Trials on Advanced Malignant Solid Neoplasm

Total 11352 results

University of California, San Francisco

Completed

Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Canada
National Cancer Institute (NCI)

Not yet recruiting

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
National Cancer Institute (NCI)

Recruiting

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Terminated

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

FID-007 in Treating Participants With Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Ronald Levy
Bristol-Myers Squibb

Completed

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Extracranial Solid Neoplasm

United States
National Cancer Institute (NCI)

Not yet recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm
M.D. Anderson Cancer Center

Recruiting

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Not yet recruiting

Adoption of Audio Recording in the Outpatient Supportive Care Center

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer

Advanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Terminated

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid Neoplasm

United States, Canada
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Not yet recruiting

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Refractory Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
Advanced Integrative Medical Science Institute

Recruiting

AIMS Cancer Outcomes Study (ACOS)

Neoplasms | Advanced Solid Tumor | Advanced Cancer | Oncology | Neoplasm Malignant

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Withdrawn

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone
M.D. Anderson Cancer Center

Recruiting

Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit

Hematopoietic and Lymphoid Cell Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the Lung

United States
M.D. Anderson Cancer Center

Active, not recruiting

Technology-Enhanced Palliative Care for Advanced Cancer Patients

Advanced Malignant Solid Neoplasm

United States
Tianhong Li
National Cancer Institute (NCI); OncoImmune, Inc.

Terminated

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

Advanced Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center

Recruiting

Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers

Advanced Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Advanced Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Advanced Malignant Solid Neoplasm

United States
Sameek Roychowdhury

Active, not recruiting

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Cholangiocarcinoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Daiichi Sankyo Co., Ltd.

Recruiting

Study of Ifinatamab Deruxtecan (I-DXd) in Participants With Advanced Solid Malignant Tumors

Advanced Solid Tumor | Malignant Solid Tumor

United States, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm

United States
Tianhong Li
National Cancer Institute (NCI); LabyRx Immunologic Therapeutics

Recruiting

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Adenocarcinoma | Advanced Adenocarcinoma | Recurrent Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

Locally Advanced Malignant Solid Neoplasm

United States
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
National Cancer Institute (NCI)

Recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast Carcinoma

United States
BioNTech SE
Genmab

Recruiting

Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors

Advanced Malignant Solid Tumor

United States, United Kingdom
Stemirna Therapeutics
Peking University Cancer Hospital & Institute

Not yet recruiting

Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors
Hutchmed

Recruiting

A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Shanghai Virogin Biotech Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors

Advanced Malignant Solid Tumor

China

Clinical Trials on Advanced Malignant Solid Neoplasm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations